Free Trial
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Vertex Pharmaceuticals logo
$410.28 +7.38 (+1.83%)
Closing price 04:00 PM Eastern
Extended Trading
$410.50 +0.22 (+0.05%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Advanced

Key Stats

Today's Range
$400.86
$413.29
50-Day Range
$366.54
$472.27
52-Week Range
$362.50
$519.88
Volume
1.59 million shs
Average Volume
1.65 million shs
Market Capitalization
$105.19 billion
P/E Ratio
29.33
Dividend Yield
N/A
Price Target
$493.81
Consensus Rating
Moderate Buy

Company Overview

Vertex Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

VRTX MarketRank™: 

Vertex Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 33rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 16 buy ratings, 12 hold ratings, and no sell ratings.

  • Upside Potential

    Vertex Pharmaceuticals has a consensus price target of $493.81, representing about 19.8% upside from its current price of $412.30.

  • Amount of Analyst Coverage

    Vertex Pharmaceuticals has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vertex Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vertex Pharmaceuticals is 29.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.49.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vertex Pharmaceuticals is 29.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.72.

  • Price to Book Value per Share Ratio

    Vertex Pharmaceuticals has a P/B Ratio of 6.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vertex Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.58% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently increased by 11.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vertex Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vertex Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.58% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently increased by 11.26%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Vertex Pharmaceuticals has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 40 news articles for Vertex Pharmaceuticals this week, compared to 40 articles on an average week.
  • Search Interest

    71 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • MarketBeat Follows

    39 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 290% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vertex Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,948,400.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vertex Pharmaceuticals' insider trading history.
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Stock News Headlines

What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet?
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
2 Beaten-Down Stocks Primed for a Comeback
See More Headlines

VRTX Stock Analysis - Frequently Asked Questions

Vertex Pharmaceuticals' stock was trading at $402.70 at the beginning of 2025. Since then, VRTX stock has increased by 2.4% and is now trading at $412.3030.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Monday, August, 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating the consensus estimate of $4.24 by $0.28. The firm's quarterly revenue was up 11.3% compared to the same quarter last year.
Read the conference call transcript
.

Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others.

Vertex Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.30%), Gradient Investments LLC (0.02%), Shorepoint Capital Partners LLC and Graphene Investments SAS. Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Edward Morrow Atkinson III, Jonathan Biller, Jeffrey M Leiden, Kristen Ambrose, Sangeeta N Bhatia and Yuchun Lee.
View institutional ownership trends
.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
8/04/2025
Today
10/07/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CIK
875320
Employees
6,100
Year Founded
1989

Price Target and Rating

High Price Target
$575.00
Low Price Target
$405.00
Potential Upside/Downside
+20.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
29 Analysts

Profitability

EPS (Trailing Twelve Months)
$13.99
Trailing P/E Ratio
29.22
Forward P/E Ratio
26.16
P/E Growth
N/A
Net Income
-$535.60 million
Net Margins
31.86%
Pretax Margin
38.31%
Return on Equity
23.91%
Return on Assets
17.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.52
Quick Ratio
2.16

Sales & Book Value

Annual Sales
$11.02 billion
Price / Sales
9.51
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$63.72 per share
Price / Book
6.42

Miscellaneous

Outstanding Shares
256,390,000
Free Float
255,878,000
Market Cap
$104.82 billion
Optionable
Optionable
Beta
0.43

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:VRTX) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners